CTLA4 and heart disorder: Lyon et al. (20) suggested that immune combination therapy (anti-PD1 plus anti-CTLA4), preexisting cardiac disease, previous autoimmune disease, and the expression of cardiac antigens in the tumor tissue may all predispose patients to immune checkpoint-mediated cardiotoxic effects (20).